LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Kodu・Aktsiate loetelu・Glaukos Corp

Glaukos Corp

Suletud

SektorTervishoid

90.82 -1.09

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

91.84

Põhinäitajad
By Trading Economics
Sissetulek	-1.5M -20M
Müük	17M 124M
Kasumimarginaal	-15.837
Töötajad	995
EBITDA	-513K -21M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+29.77% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. nov 2025

Turustatistika
By TradingEconomics
Turukapital	72M 5.5B
Eelmine avamishind	91.91
Eelmine sulgemishind	90.82

Uudiste sentiment

By Acuity

84%

16%

138 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

87.61 / 93 Toetus ja vastupanu

Glaukos Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. sept 2025, 23:37 UTC

Kuumad aktsiad

Stocks to Watch: Oracle, Wearable Devices, GameStop

9. sept 2025, 20:41 UTC

Tulu

Oracle's Backlog Surges With Major Customer Deals in 1Q

9. sept 2025, 20:30 UTC

Tulu

GameStop 2Q Sales, Profit Rise

9. sept 2025, 23:19 UTC

Market Talk

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9. sept 2025, 21:35 UTC

Tulu

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9. sept 2025, 21:32 UTC

Tulu

Oracle's Backlog Swells With Big Customer Deals -- Update

9. sept 2025, 21:02 UTC

Omandamised, ülevõtmised, äriostud

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. sept 2025, 20:33 UTC

Tulu

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9. sept 2025, 20:26 UTC

Tulu

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9. sept 2025, 20:23 UTC

Tulu

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9. sept 2025, 20:12 UTC

Tulu

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9. sept 2025, 20:10 UTC

Tulu

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9. sept 2025, 20:10 UTC

Tulu

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9. sept 2025, 20:09 UTC

Tulu

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9. sept 2025, 20:09 UTC

Tulu

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9. sept 2025, 20:08 UTC

Tulu

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9. sept 2025, 20:08 UTC

Tulu

Oracle 1Q Operating Income Was $4.3 B >ORCL

9. sept 2025, 20:08 UTC

Tulu

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9. sept 2025, 20:08 UTC

Tulu

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9. sept 2025, 20:07 UTC

Tulu

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9. sept 2025, 20:06 UTC

Tulu

Oracle 1Q Software Revenue $5.72B >ORCL

9. sept 2025, 20:06 UTC

Tulu

Synopsys 3Q Adj EPS $3.39 >SNPS

9. sept 2025, 20:06 UTC

Tulu

Oracle 1Q Cloud Revenue $7.19B >ORCL

9. sept 2025, 20:05 UTC

Tulu

Oracle 1Q Rev $14.93B >ORCL

9. sept 2025, 20:05 UTC

Tulu

Oracle 1Q EPS $1.01 >ORCL

9. sept 2025, 20:05 UTC

Tulu

Synopsys 3Q EPS $1.50 >SNPS

9. sept 2025, 20:05 UTC

Tulu

Oracle 1Q Services Revenue $1.35B >ORCL

9. sept 2025, 20:05 UTC

Tulu

Oracle 1Q Adj EPS $1.47 >ORCL

9. sept 2025, 20:05 UTC

Tulu

Oracle 1Q Hardware Revenue $670M >ORCL

Võrdlus sarnastega

Hinnamuutus

Glaukos Corp Prognoos

Hinnasiht

By TipRanks

29.77% tõus

12 kuu keskmine prognoos

Keskmine 121.91 USD 29.77%

Kõrge 165 USD

Madal 92 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Glaukos Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Glaukos Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

87.61 / 93Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

138 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.